Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL

Plain-language summary

This single-center, open-label, single-arm, prospective Phase 1/2 study evaluates the safety, tolerability and efficacy of dual-target CD22/CD19 CAR-T cell therapy as consolidation treatment in patients with standard-risk B-cell acute lymphoblastic leukemia (B-ALL) in remission. Eligible patients undergo leukapheresis for CAR-T manufacturing, then lymphodepleting chemotherapy and CAR-T infusion, with close monitoring for cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), hematologic toxicity and infections. Participants must provide written informed consent, be able to comply with study procedures, and have cytologically or histologically confirmed B-ALL.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

PHASE1/PHASE2

Status

Recruiting

Sponsor

Liping Dou

Intervention

CD22/CD19 Dual-Target CAR-T Cells

Start date

1/1/2026

Estimated completion

12/31/2027

Countries

China

Locations

• Beijing, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. Patients who have provided written informed consent and are willing and able to comply with study procedures, including scheduled visits, treatment, laboratory tests, and other study-related assessments.
2. Patients with cytologically or histologically confirmed B-cell acute lymphoblastic leukemia/lymphoma (B-ALL/LBL) according to WHO 2022 criteria, with CD19-positive and/or CD22-positive disease. Patients must have achieved first morphological complete remission (CR1; bone marrow blasts \<5%) after standard induction chemotherapy. Patients may or may not have achieved deep remission, defined as minimal residual disease (MRD) negativity assessed by flow cytometry and/or molecular methods (e.g., quantitative PCR or next-generation sequencing).
3. Adult patients with standard-risk B-cell acute lymphoblastic leukemia , as defined by cytogenetic and molecular risk stratification and without high-risk features, who have achieved complete remission (CR) after treatment, received two cycles of long-course intensive consolidation chemotherapy, maintained sustained bone marrow MRD negativity by multiparameter flow cytometry (MFC) and sustained molecular MRD negativity by real-time quantitative polymerase chain reaction (RT-qPCR) or next-generation sequencing (NGS), are not considered to require allogeneic hematopoietic stem cell transplantation (allo-HSCT) for consolidation, and refuse or are ineligible to receive CD19/CD3 bispecific antibody therapy (e.g., blinatumomab), and are therefore planned to receive CAR-T cell immunotherapy as enhanced consolidation therapy followed by long-term maintenance treatment.
4. Age between 18 and 85 years, regardless of sex.
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
6. Estimated life expectancy ≥3 months.
7. Hemoglobin ≥60 g/L (transfusion allowed).
8. Absolute neutrophil count ≥1,000/μL and platelet count ≥45,000/μL.
9. Adequate organ function, defined as:

Total bilirubin ≤1.5 × upper limit of normal (ULN) (except Gilbert's syndrome); ALT and AST ≤2.5 × ULN; Serum creatinine ≤1.5 × ULN or creatinine clearance ≥60 mL/min (Cockcroft-Gault formula); Left ventricular ejection fraction (LVEF) ≥50%, no clinically significant arrhythmia, and no pericardial effusion; Baseline oxygen saturation \>92% on room air; No clinically significant pleural effusion.

10\. Subjects of reproductive potential must agree to use effective contraception from enrollment until at least 6 months after completion of the study. Subjects who are pregnant or suspected to be pregnant must notify the investigator immediately.

Exclusion Criteria:

1. Patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), or with risk factors indicating the need for allogeneic hematopoietic stem cell transplantation, who are planned to receive allogeneic hematopoietic stem cell transplantation or CD19/CD3 bispecific antibody (blinatumomab) therapy and refuse CAR-T cell immunotherapy as consolidation treatment, including any of the following conditions:

   ① Early relapse within 6 months after achieving first complete remission;

   ② Primary refractory disease, defined as failure to achieve first morphological complete remission after two cycles of standard first-line induction chemotherapy;

   ③ Failure to achieve complete remission or relapse after first-line or multiple lines of salvage chemotherapy;

   ④ Relapse after allogeneic hematopoietic stem cell transplantation;

   ⑤ Persistent MRD positivity with a high risk of relapse.
2. Prior treatment with any CAR-T cell therapy or other genetically modified T-cell therapies.
3. Known history of HIV infection, active hepatitis B virus (HBV) infection, or any uncontrolled active systemic infection requiring intravenous antibiotics.

   (Active HBV infection is defined as: HBV DNA ≥2000 IU/mL, ALT ≥2×ULN, and exclusion of other causes of hepatitis.)
4. Non-disease-related hepatic or renal dysfunction defined as:

   ALT or AST \>3×ULN; Total bilirubin \>2×ULN; Creatinine clearance \<30 mL/min.
5. History of significant cardiovascular disease within 12 months prior to enrollment, including myocardial infarction, coronary intervention, unstable angina, or clinically significant arrhythmia.
6. Other severe or uncontrolled medical conditions that may interfere with study participation or outcomes, including but not limited to uncontrolled diabetes, severe gastrointestinal disease, severe cardiopulmonary disease, autoimmune disease, immunodeficiency, or uncontrolled infections.
7. History of severe immediate hypersensitivity reactions to study-related drugs, aminoglycosides, or biologic agents.
8. Pregnant or breastfeeding women.
9. Patients who are unable or unwilling to comply with study procedures or follow-up, or who have poor adherence as judged by the investigator.
10. History of other malignancies unless disease-free for at least 3 years without active treatment (except for adequately treated non-melanoma skin cancer or carcinoma in situ).
11. Receipt of live vaccines within 6 weeks prior to initiation of lymphodepleting chemotherapy.
12. Major surgery within 14 days prior to enrollment or planned major surgery during the study period.
13. Any other condition that, in the investigator's judgment, may increase risk, interfere with study results, or make the patient unsuitable for the study.